サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1702376

血栓性血小板減少性紫斑病（TTP）の世界市場：2025年～2033年

Global Thrombotic Thrombocytopenic Purpura (TTP) Market - 2025-2033

出版日
ページ情報
英文 198 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
血栓性血小板減少性紫斑病（TTP）の世界市場：2025年～2033年
出版日: 2025年04月10日
発行: DataM Intelligence
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の血栓性血小板減少性紫斑病（TTP）の市場規模は、2024年に12億5,000万米ドルに達し、2033年には18億5,000万米ドルに達すると予測され、2025年から2033年の予測期間中に4.5％のCAGRで拡大する見込みです。

血栓性血小板減少性紫斑病（TTP）は、広範な微小血管血栓症（血管内の小さな血栓）、重度の血小板減少症（血小板数の減少）、微小血管障害性溶血性貧血（MAHA）を特徴とする、生命を脅かすまれな血液疾患です。この疾患は主に、血液凝固に関与する重要なタンパク質であるフォンウィルブランド因子（vWF）の調節を担うADAMTS13酵素の欠損または機能不全によって引き起こされます。早期介入と継続的モニタリングが生存と長期管理の鍵です。

新規製品の上市が血栓性血小板減少性紫斑病市場の成長を大きく牽引しています。

新規製品の上市がTTP市場の成長を牽引していることは否定できません。生命を脅かすこの稀な疾患に対して、より的を絞った効果的で利便性の高い治療を提供するからです。カプラシズマブの承認、ADAMTS13置換療法の進歩、遺伝子治療の可能性、リツキシマブの使用拡大などはすべて、TTP治療の展望を変える上で極めて重要な役割を果たしています。これらの技術革新は、患者の転帰の改善、再発の減少、市場需要の全体的増加につながり、今後数年間のTTP市場の成長を促進します。

例えば、武田薬品工業は2023年11月、米国食品医薬品局（FDA）から、成人および小児の先天性血栓性血小板減少性紫斑病（cTTP）の予防的治療薬およびオンデマンド治療薬としてADZYNMA（ADAMTS13、遺伝子組換えkrhn）を承認されたと発表しました。ADZYNMAは、欠損したADAMTS13酵素を置換することで、cTTP患者におけるアンメット・メディカル・ニーズに対応するようデザインされた、最初で唯一のFDA承認済み遺伝子組換えADAMTS13（rADAMTS13）蛋白質です。

さらに、Sanofiが開発したモノクローナル抗体であるカプラシズマブは、後天性TTPの治療薬として2019年にFDAから承認されました。これは、von Willebrand因子（vWF）に結合して血小板凝集と血栓形成を阻止することにより作用するファースト・イン・クラスの治療薬です。

血漿交換療法はコストと手間がかかり、専門的な医療インフラを必要とします。この血漿交換への依存は治療費全体に大きく寄与し、特に低資源環境では患者やヘルスケアシステムにとって大きな障壁となっています。この手技には、特殊な機器、訓練を受けたスタッフ、十分な血液供給が必要です。このため、適切な医療施設がない地域、特に低所得国や農村部では、PEXの利用が制限されています。

PEXは一刻を争うものであり、効果的な結果を得るためには、診断後直ちに開始する必要があります。開始が遅れると、特に急性TTP患者では死亡率が高くなります。PEX治療センターが乏しかったり、容易に利用できなかったりする地域では、患者がタイムリーな治療を受けられず、予後不良やヘルスケア負担の増加につながる可能性があります。

全体として、血漿交換（PEX）への依存はTTP市場の成長をさまざまな面で阻害しています。血漿交換は、治療プロセスに多大なコスト、リソースの制約、患者へのアクセスの問題をもたらします。さらに、PEXには合併症のリスク、限られたインフラ、血漿不足の深刻化などがあり、長期的には望ましくないです。カプラシズマブのような生物学的製剤の出現や遺伝子治療の探求により、PEXへの依存は徐々に減少し、より効果的で資源集約的でない代替療法が提供されつつあります。このような治療パラダイムの転換により、TTP市場は大きく変化し、将来的にはより持続的な成長が見込まれます。

当レポートでは、世界の血栓性血小板減少性紫斑病（TTP）市場について調査し、市場の概要とともに、疾患タイプ別、治療タイプ別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界見通し

  • 市場のリーダーとパイオニア
  • 最新の開発とブレークスルー
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向

第5章 血栓性血小板減少性紫斑病（TTP）市場（疾患タイプ別）

  • 遺伝性（先天性）TTP
  • 獲得性（免疫介在性）TTP

第6章 血栓性血小板減少性紫斑病（TTP）市場、治療タイプ別

  • 血漿交換
  • コルチコステロイド
  • リツキシマブ
  • 酵素補充療法
  • その他

第7章 血栓性血小板減少性紫斑病（TTP）市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • 学術研究機関
  • その他

第8章 血栓性血小板減少性紫斑病（TTP）市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要市場参入企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Takeda Pharmaceutical Company Limited
    • 会社概要
    • 製品ポートフォリオ
    • 財務概要
    • 主な発展
    • SWOT分析
  • Sanofi
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sandoz Group AG
  • Fresenius Kabi USA, LLC
  • Hikma Pharmaceuticals PLC
  • Teva Pharmaceutical Industries Ltd.

第11章 仮定と調査手法

第12章 付録

目次
Product Code: PH6568

The global thrombotic thrombocytopenic purpura (TTP) market size reached US$ 1.25 billion in 2024 and is expected to reach US$ 1.85 billion by 2033, growing at a CAGR of 4.5% during the forecast period of 2025-2033.

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening hematologic disorder characterized by widespread microvascular thrombosis (small blood clots in the blood vessels), severe thrombocytopenia (low platelet count), and microangiopathic hemolytic anemia (MAHA). The disease is primarily caused by a deficiency or dysfunction of the ADAMTS13 enzyme, which is responsible for regulating the von Willebrand factor (vWF), a key protein involved in blood clotting. Early intervention and continuous monitoring are key to survival and long-term management.

Market Dynamics: Drivers & Restraints

Novel product launches are significantly driving the thrombotic thrombocytopenic purpura market growth.

Novel product launches are undeniably driving the growth of the TTP market, as they offer more targeted, effective, and convenient treatments for this rare, life-threatening disorder. The approval of Caplacizumab, advancements in ADAMTS13 replacement therapies, the potential of gene therapy, and the expanding use of Rituximab are all playing pivotal roles in transforming the TTP treatment landscape. These innovations are leading to better patient outcomes, fewer relapses, and an overall increase in market demand, propelling the TTP market's growth in the coming years.

For instance, in November 2023, Takeda announced that the U.S. Food and Drug Administration (FDA) had approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.

Additionally, caplacizumab, a monoclonal antibody developed by Sanofi, was approved by the FDA in 2019 for the treatment of acquired TTP. It is a first-in-class therapy that works by binding to the von Willebrand Factor (vWF) to prevent platelet aggregation and the formation of blood clots.

Dependence on plasma exchange (PEX) is hampering the market growth

Plasma exchange therapy is costly and labor-intensive and requires specialized medical infrastructure. This dependence on PEX contributes significantly to the overall treatment cost, which is a major barrier for patients and healthcare systems, especially in low-resource settings. The procedure requires specialized equipment, trained staff, and an adequate blood supply. This restricts the availability of PEX in areas lacking proper medical facilities, especially in low-income countries or rural settings.

PEX is time-sensitive and needs to be initiated immediately upon diagnosis for effective outcomes. Delayed initiation can lead to higher mortality rates, especially in patients with acute TTP. In areas where PEX treatment centers are scarce or not readily available, patients may not receive timely care, leading to poor prognosis and increased healthcare burden.

Overall, the dependence on Plasma Exchange (PEX) is hampering the growth of the TTP market in multiple ways. It adds significant costs, resource constraints, and patient accessibility issues to the treatment process. Additionally, PEX comes with risks of complications, limited infrastructure, and a growing plasma shortage, all of which make it less desirable in the long run. The emergence of biologic therapies like Caplacizumab and the exploration of gene therapies are gradually reducing the reliance on PEX, offering more effective and less resource-intensive alternatives. These shifts in treatment paradigms are expected to transform the TTP market and drive more sustainable growth in the future.

Segment Analysis

The global thrombotic thrombocytopenic purpura (TTP) market is segmented based on disease type, treatment type, end-user, and region.

Treatment Type:

The plasma exchange/plasmapheresis segment is expected to dominate the thrombotic thrombocytopenic purpura (TTP) market with the highest market share.

Plasma exchange is considered the first-line treatment for acute TTP, which is a life-threatening medical emergency. Immediate plasma exchange is essential to remove autoantibodies that inhibit the ADAMTS13 enzyme, which is responsible for cleaving the von Willebrand factor (vWF). PEX also replaces deficient plasma proteins and restores normal blood clotting mechanisms. Without PEX, the mortality rate of TTP can exceed 90%, but early initiation of PEX reduces the mortality rate to less than 10%.

While newer therapies like Caplacizumab (Cablivi) have introduced additional treatment options, PEX continues to play a complementary role. Caplacizumab is often used in combination with PEX to enhance clinical outcomes. PEX is used initially to stabilize the patient, followed by Caplacizumab or other biologics for long-term disease management, reducing the frequency of relapses.

The Plasma Exchange (PEX) segment is expected to dominate the TTP market for the foreseeable future due to its proven efficacy, timely intervention, widespread availability, and cost-effectiveness. Despite the emergence of biologics like Caplacizumab, PEX remains the cornerstone of treatment for acute TTP and continues to play a key role in managing relapsing or refractory cases. As a result, PEX will maintain its market leadership, particularly in emergency care settings and for severe acute TTP episodes, while newer therapies complement its usage for long-term management.

Geographical Analysis

North America is expected to hold a significant position in the global thrombotic thrombocytopenic purpura (TTP) market with the highest market share

North America, especially the United States, leads in the development and adoption of innovative therapies for TTP. Caplacizumab (Cablivi), a monoclonal antibody approved for TTP, was first introduced in North America in 2019. The FDA's expedited approval process for novel treatments has allowed North America to be at the forefront of cutting-edge therapies, reducing the dependency on traditional treatments like plasma exchange (PEX).

North America has well-established regulatory frameworks that facilitate the approval and availability of treatments for rare diseases like TTP. Furthermore, insurance coverage for rare diseases is relatively high in North America, which ensures that patients have access to high-cost treatments like plasma exchange (PEX) and biologics.

North America's advanced healthcare systems, high incidence of TTP, pioneering role in innovative treatments, and strong regulatory support. The FDA's approval processes, the presence of leading pharmaceutical companies, and the focus on rare diseases all contribute to the region's position as the primary market for TTP treatments. With a growing number of TTP new therapies entering the market, North America is expected to remain the largest and most influential market for TTP management in the years to come.

Competitive Landscape

Top companies in the thrombotic thrombocytopenic purpura market include Takeda Pharmaceutical Company Limited, Sanofi, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sandoz Group AG, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., and others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global thrombotic thrombocytopenic purpura (TTP) market report delivers a detailed analysis with 56 key tables, more than 52 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Disease Type
  • 2.4. Snippet by Treatment Type
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Novel Product Launches
      • 3.1.1.2. Emergence of Novel Biological Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Treatment
      • 3.1.2.2. Dependence on Plasma Exchange (PEX)
    • 3.1.3. Opportunity
      • 3.1.3.1. AI & Machine Learning in Treatment Optimization
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with the Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics

5. Thrombotic Thrombocytopenic Purpura (TTP) Market, By Disease Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 5.1.2. Market Attractiveness Index, By Disease Type
  • 5.2. Inherited (Congenital) TTP*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Acquired (Immune-Mediated) TTP

6. Thrombotic Thrombocytopenic Purpura (TTP) Market, By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index, By Treatment Type
  • 6.2. Plasma Exchange / Plasmapheresis*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Corticosteroids
  • 6.4. Rituximab
  • 6.5. Enzyme Replacement Therapy
  • 6.6. Others

7. Thrombotic Thrombocytopenic Purpura (TTP) Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Academic and Research Institutes
  • 7.5. Others

8. Thrombotic Thrombocytopenic Purpura (TTP) Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Takeda Pharmaceutical Company Limited*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Sanofi
  • 10.3. Pfizer Inc.
  • 10.4. F. Hoffmann-La Roche Ltd
  • 10.5. Sandoz Group AG
  • 10.6. Fresenius Kabi USA, LLC
  • 10.7. Hikma Pharmaceuticals PLC
  • 10.8. Teva Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us